The Atellica IM High-Sensitivity Troponin I assay aids in rapid AMI detection and now integrates cTn values as a prognostic indicator to help predict risk of cardiac events and death for up to one year in symptomatic patients. This innovative prognostic claim supports more informed clinical decisions and has the potential to both reduce healthcare burden from repeated emergency visits and help prevent adverse cardiac outcomes.